High False-Positive Rate of (1,3)-β-D-Glucan in Onco-Hematological Patients Receiving Immunoglobulins and Therapeutic Antibodies.
false-positive
intravenous immunoglobulines
onco-hematology
therapeutic antibodies
β-D-glucan
Journal
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213
Informations de publication
Date de publication:
25 08 2022
25 08 2022
Historique:
received:
10
12
2021
pubmed:
8
1
2022
medline:
30
8
2022
entrez:
7
1
2022
Statut:
ppublish
Résumé
Immunoglobulins and/or therapeutic antibody preparations are associated with a high rate of false-positive (1,3)-β-D-glucan (BDG) tests in onco-hematological patients routinely screened for fungal infections. The benefit of BDG monitoring shall be balanced against the risk of false-positive tests leading to unnecessary investigations and costs in this population.
Identifiants
pubmed: 34996098
pii: 6498297
doi: 10.1093/cid/ciab1028
doi:
Substances chimiques
Glucans
0
Immunoglobulins
0
Proteoglycans
0
beta-Glucans
0
polysaccharide-K
3X48A86C8K
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
330-333Informations de copyright
© The Author(s) 2022. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.